China Pharma Holdings, Inc. entered into a securities purchase agreement on July 22, 2026, to issue 2,500,000 shares of common stock at $2.00 per share in a registered direct offering, generating $5,000,000 in gross proceeds. The offering is expected to close on July 23, 2026, with FT Global Capital, Inc. acting as the exclusive placement agent. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets products for cardiovascular, CNS, infectious, and digestive diseases in China.